Loading clinical trials...

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas

NCT02401048•Pharmacyclics LLC.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)
•Measurable disease sites on CT scan (\>1.5 cm in longest dimension)
•Adequate hematologic function:
•1. Absolute Neutrophil Count \>1500 cells/mm3
•2. Platelets \>50000 cells/mm3
•3. Hemoglobin \>8.0 g/dL
•Adequate hepatic and renal function:
•1. AST or ALT ≤2.5 x ULN
•2. Bilirubin ≤1.5 x ULN
•3. Estimated creatinine clearance (Cockcroft-Gault) \>40 mL/min
+1 more criteria

Exclusion Criteria

•Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody
•Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor
•Primary CNS lymphoma or evidence of CNS involvement by lymphoma

Locations (11)

Site-0397

Birmingham, Alabama, United States

Site-0047

Duarte, California, United States

Site-0038

Stanford, California, United States

Site-0388

Miami, Florida, United States

Site-0126

Chicago, Illinois, United States

Site-0020/0173

Boston, Massachusetts, United States

Site-0729

Ann Arbor, Michigan, United States

Site-0130

Detroit, Michigan, United States

Site-0343

Hackensack, New Jersey, United States

Site-0402

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

May 1, 2015

Primary Completion Date

November 1, 2017

Completion Date

November 1, 2017

Last Updated

June 27, 2019

Enrollment

ACTUAL participants

Conditions

Diffuse Large B-Cell LymphomaFollicular Lymphoma

Interventions

Ibrutinib

DRUG

MEDI4736

DRUG

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View study

RECRUITINGPHASE2/PHASE3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

DLBCLDiffuse Large B-Cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 27, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Inclusion Criteria

Exclusion Criteria

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Odronextamab in Low Tumor Volume Advanced FL